Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer&apos;s disease by M. Ventriglia et al.
Molecular Psychiatry (2002) 7, 136–139
 2002 Nature Publishing Group All rights reserved 1359-4184/02 $25.00
www.nature.com/mp
SCIENTIFIC CORRESPONDENCE
Association between the
BDNF 196 A/G polymorphism
and sporadic Alzheimer’s
disease
Molecular Psychiatry (2002) 7, 136–137. DOI: 10.1038/
sj/mp/4000952
SIR – Alzheimer’s disease (AD) is a chronic brain dis-
order associated with specific pathological changes
resulting in neurodegeneration and in progressive
development of dementia. This disease is clinically
characterized by memory, reasoning and speech dis-
orders and pathologically by the presence of senile pla-
ques (SP), neurofibrillary tangles, and loss of syn-
apses.1 There are various hypotheses regarding an
involvement of genetic factors in the development of
AD. Mutations of genes encoding amyloid precursor
protein, presenilin-1 and presenilin-2 cause familial
AD,2,3 and the 4 allele of apolipoprotein E (APOE)
gene gives susceptibility to familial and sporadic AD.4
However, this genetic marker cannot explain the over-
all genetic susceptibility and additional/other genes
may be involved in the development of AD.
Genes involved in the neurodevelopmental process
may be considered good candidates to confer suscepti-
bility to AD. Brain-derived neurotrophic factor (BDNF)
is a member of the neurotrophin family of growth fac-
tors which promotes survival, differentiation and
maintenance of neurons in peripheral and central ner-
vous system during normal development,5 influences
axonal growth and connectivity6 and participates in
the local responses to various types of neuronal stress
or insults.7
Table 1 Allele and genotype frequencies of the BDNF gene polymorphism at position 196 in Alzheimer patients and controls
Alzheimer patients (n = 130) Healthy volunteers (n = 111)
BDNF allele frequency
Allele G 203 (78%) 156 (70.3%)
Allele A 57 (22%) 66 (29.7%)
2 = 3.340 (df = 1) P = 0.063
BDNF genotype Total 4 + (65) 4 − (65) Total
GG 85 (65.4%) 43 (66.2%) 42 (64.6%) 54 (48.7%)
GA 33 (25.4%) 14 (21.5%) 19 (29.2%) 48 (43.2%)
AA 12 (9.2%) 8 (12.3%) 4 (6.2%) 9 (8.1%)
2 = 8.68 (df = 2) P = 0.013
If G allele recessive:
2 = 6.202, P = 0.013 OR = 1.994 (95% CI 1.149–3.466)
Several lines of evidence have suggested altered
functions of this gene in the pathogenesis of neurodeg-
enerative diseases including Alzheimer’s disease:
reduced levels of BDNF mRNA in the hippocampus, in
the temporal cortex, in brain homogenates and in fron-
tal cortex neurons have been found in individuals
with AD.8
In order to verify a potential role of the BDNF gene
in the neuropathogenesis of Alzheimer’s disease, we
analyzed allelic distribution of a polymorphism in the
coding region of the BDNF gene in a diagnosed AD
sample and in a control group.
The polymorphism studied is a A/G (Met/Val) sub-
stitution located in the propeptide region, a highly
unstable region constituted by 110 aa, in the BDNF
gene at position 196 (codon 66) (SWISS.PROT:
P23560.VAR 004626).
Genomic DNA was extracted from blood samples
obtained, after informed consent, from 130 Alzheimer’s
patients (mean age 72 ± 3 years; 90 women and 40 men)
recruited at the Alzheimer Unit of IRCCS-Fatebenefrat-
elli (Brescia, Italy) and 111 healthy ethnically and age-
matched volunteers. Patients and controls were Cauca-
sians living in Northern Italy.
Genotyping for this polymorphism has been done by
PCR amplification with suitable primers: (forward: 5-
ACT CTG GAG AGC GTG AAT GG 3, reverse: 5-TCC
AGG GTG ATG CTC AGT AGT-3) and enzymatic
digestion with restriction enzyme PmaCI, followed by
polyacrylamide gel electrophoresis with ethidium bro-
mide staining.
The BDNF genotypes and allele frequencies in
patients and controls are shown in Table 1. Allele fre-
quencies were calculated by gene counting and differ-
ences between groups were evaluated by the 2 test.
The genotyping distribution in both patients and con-
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trols was within Hardy–Weinberg equilibrium. Odds
ratio (OD) and their 95% confidence intervals were cal-
culated to evaluate effects of different genotypes. We
found a difference in the frequency of A/G alleles
between the total amount of patients studied and con-
trols which comes close to statistical significance (2 =
3.440; P = 0.063). The genotype distributions differed
significantly in patients with AD compared to the con-
trols (2 = 8.68; P = 0.013). The frequency of individ-
uals who carried two copies of the Val allele was sig-
nificantly increased in patients than in controls (2 =
6.202; P = 0.013, odds ratio: 1.994, 95% CI 1.15–3.46),
suggesting that homozygosity for the Val allele confers
an increased risk for AD.
In order to examine the possible interaction between
AD and APOE, we genotyped the 130 AD patients and
we found 65 carrying the 4 allele of APOE gene. There
was no significant difference in the distribution of
allele frequencies between the two groups (2 = 0.090,
df = 1, P = 0.76) (Table 1), and we concluded that poss-
ible effects of Val on susceptibility to AD might be
independent from the APOE genotype. These data are
in agreement with a recent observation of association
of another BDNF gene polymorphism (C270T in the
5UTR) to late onset AD in the Japanese population.9
Further studies are needed to confirm the relationship
of two polymorphisms including a possible linkage
disequilibrium.
In conclusion these results make the BDNF an
important candidate gene for susceptibility of AD and
might provide a baseline to rationalize the use of neur-
otrophins as possible therapeutic agents in specific
human neurodegenerative diseases.
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SIR – Tardive dyskinesia (TD) is a serious, treatment-
refractory movement disorder which develops in
patients chronically exposed to antipsychotic drugs
that block dopamine D2 receptors. Since, on average,
only about one fifth of patients develop the disorder,1
there is considerable interest in identifying factors that
might underlie individual sensitivity. In a recent issue
of Molecular Psychiatry, we reported association of TD
with the serotonin 2A receptor gene (HTR2A).2 This
receptor is implicated in the mechanism of action of
atypical antipsychotic drugs that have a lower propen-
sity to induce TD. Our positive findings were for the
silent T102C polymorphism in the coding region and
the A-1438G polymorphism in the promoter, which
were in complete linkage disequilibrium in our sam-
ple. Patients with TD had a significant excess of 102C
and −1438G alleles and of 102CC and −1438GG geno-
types compared to patients without TD and normal
control subjects. Patients carrying the 102CC and
−1438GG genotypes had significantly higher scores on
the sub-scales of the Abnormal Involuntary Movements
Scale (AIMS) that measure dyskinetic trunk move-
ments and degree of incapacitation.
In the same issue of Molecular Psychiatry, Basile et
al,3 to whom we had communicated our unpublished
findings, reported no allelic or genotypic association
of the same polymorphisms in HTR2A with TD. Their
patients carrying 102CC and −1438GG genotypes did
not have higher AIMS total scores than patients homo-
zygous for the wild-type allele. AIMS sub-scale scores
were not reported. This disparity contrasts with similar
findings of the two groups in the same patient samples
in regard to association of the dopamine D3 receptor
gene (DRD3) with TD.4,5
Among the demographic and clinical factors that
have been associated with individual susceptibility to
TD, age is the most consistently reported. In a prospec-
tive study, Jeste et al6 found the cumulative incidence
of TD in patients who initiated treatment with antipsy-
chotic drugs after the age of 45, to be 60% after 3 years.
In other studies too, aging appears to be the most pre-
dominant patient-related risk factor for TD.7 We hypo-
thesized that there may be an interaction between
genes that predispose to TD and age whereby the effect
of such genes may be expressed to a greater extent in
older patients. Such an effect could explain the dispar-
ity between our findings2 and those of Basile et al3 in
regard to the association of HTR2A with TD. The mean
